The estimated Net Worth of Internati Maurizio Chiriva is at least $3.24 million dollars as of 9 September 2021. Dr Chiriva owns over 2,800 units of Kiromic BioPharma stock worth over $2,797,486 and over the last 3 years he sold KRBP stock worth over $0. In addition, he makes $437,900 as Founder, Chairman et CEO & Pres at Kiromic BioPharma.
Sign up
Dr D KRBP stock SEC Form 4 insiders trading
Dr has made over 1 trades of the Kiromic BioPharma stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 2,800 units of KRBP stock worth $10,360 on 9 September 2021.
The largest trade he's ever made was buying 2,800 units of Kiromic BioPharma stock on 9 September 2021 worth over $10,360. On average, Dr trades about 2,800 units every 0 days since 2021. As of 9 September 2021 he still owns at least 1,378,072 units of Kiromic BioPharma stock.
You can see the complete history of Dr Chiriva stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Maurizio Chiriva Internati Ph.D. biography
Dr. Maurizio Chiriva Internati Ph.D. is the Founder, Chairman, CEO & Pres at Kiromic BioPharma.
What is the salary of Dr D?
As the Founder, Chairman et CEO & Pres of Kiromic BioPharma, the total compensation of Dr D at Kiromic BioPharma is $437,900. There are 1 executives at Kiromic BioPharma getting paid more, with Gianluca Rotino having the highest compensation of $4,814,700.
How old is Dr D?
Dr D is 53, he's been the Founder, Chairman et CEO & Pres of Kiromic BioPharma since . There are 3 older and 2 younger executives at Kiromic BioPharma. The oldest executive at Kiromic BioPharma, Inc. is Dr. David M. Spencer, 59, who is the Chief Scientific Officer.
What's Dr D's mailing address?
Internati's mailing address filed with the SEC is C/O KIROMIC BIOPHARMA INC., 7707 FANNIN, SUITE 140, HOUSTON, TX, 77054.
Insiders trading at Kiromic BioPharma
Over the last 4 years, insiders at Kiromic BioPharma have traded over $0 worth of Kiromic BioPharma stock and bought 29,599 units worth $105,539 . The most active insiders traders include Jerry A. Schneider, Scott Dahlbeck et Pietro Bersani. On average, Kiromic BioPharma executives and independent directors trade stock every 99 days with the average trade being worth of $7,923. The most recent stock trade was executed by Pietro Bersani on 23 August 2024, trading 3,488 units of KRBP stock currently worth $7,395.
What does Kiromic BioPharma do?
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
What does Kiromic BioPharma's logo look like?
Complete history of Dr Chiriva stock trades at Kiromic BioPharma
Kiromic BioPharma executives and stock owners
Kiromic BioPharma executives and other stock owners filed with the SEC include:
-
Gianluca Rotino,
Chief Strategy & Innovation Officer and Director -
Dr. Maurizio Chiriva Internati Ph.D.,
Founder, Chairman, CEO & Pres -
Pietro Bersani CPA, J.D.,
CEO & Director -
Dr. Leonardo Mirandola Ph.D.,
Chief Scientific Officer -
Dr. Michael Ryan Ph.D.,
Chief Bioinformatics Research Computing Officer -
Dr. Scott Dahlbeck Pharm.D., M.D., PharmD,
Chief Medical Officer -
Dr. David M. Spencer,
Chief Scientific Officer -
Daniel Clark,
Chief Financial Officer -
Shannon Ralston,
10% owner -
Michael Catlin,
Director -
Pamela Misajon,
Director -
Karen Reeves,
Director -
Americo Cicchetti,
Director -
Francis X Tirelli,
Director -
Michael Nagel,
Director -
Jerry A. Schneider,
Director -
Pietro Bersani,
Chief Executive Officer -
Scott Dahlbeck,
Chief of Staff -
Tony Tontat,
CFO & COO -
Ignacio Nunez,
CHIEF OPERAT. AND MANUF. OFFI. -
Gianluca Rotino,
CHIEF STRAT & INNOV OFFICER -
Michael Charles Ryan,
See Remarks -
Internati Maurizio Chiriva,
CHIEF EXECUTIVE OFFICER -
Daniel Grant Clark,
Chief Financial Officer -
Brian Hungerford,
Chief Financial Officer